IDNA - iShares Genomics Immunology and Healthcare ETF
| Assets | $281.98M |
| NAV | $45.48 |
| Expense Ratio | 0.47% |
| PE Ratio | 28.20 |
| Beta (5Y) | 0.82 |
| Dividend (ttm) | $0.12 |
| Dividend Yield | 0.26% |
| Ex-Dividend Date | Dec 14, 2020 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $46.67 |
| Previous Close | $45.43 |
| Change ($) | 1.24 |
| Change (%) | 2.73% |
| Day's Open | 45.33 |
| Day's Range | 45.04 - 46.71 |
| Day's Volume | 55,729 |
| 52-Week Range | 30.46 - 55.03 |
Fund Description
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
| Asset Class Equity | Inception Date Jun 11, 2019 |
| Exchange NYSEARCA | Ticker Symbol IDNA |
| Index Tracked NYSE FactSet Global Genomics and Immuno Biopharma Index | |
Top 10 Holdings
43.45% of assets| Name | Symbol | Weight |
|---|---|---|
| BeiGene Ltd Ordinary Shares | 6160.HK | 5.86% |
| Exelixis | EXEL | 4.99% |
| Fate Therapeutics | FATE | 4.88% |
| Gilead Sciences | GILD | 4.31% |
| Merck KGaA | MRK.DE | 4.20% |
| Sanofi SA | SAN.PA | 3.99% |
| Regeneron Pharmaceuticals | REGN | 3.96% |
| BioNTech SE | BNTX | 3.82% |
| Takeda Pharmaceutical Co Ltd | 4502.T | 3.77% |
| Evotec SE | EVT.DE | 3.66% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 14, 2020 | $0.036 | Dec 18, 2020 |
| Jun 15, 2020 | $0.084 | Jun 19, 2020 |
As investors re-allocate in 2021, it is critical to look past the headlines to the overarching themes that will propel our economy into the future. Investors cannot afford to miss developments like digi...
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Megatrends To Invest In Now: 3 Best ETF Picks
BlackRock has identified five big trends that are here to stay for the long haul. Investors can get exposure to these drivers via 17 iShares ETFs.
ETF investors looking ahead to 2021 tend to seek out current trends, but the megatrends run much deeper. These are the large-scale undercurrents that can disrupt a whole sector.
The best biotech ETFs for Q1 2021 are ARKG, BTEC, and IDNA.
The election year and the coronavirus has highlighted the importance of an adaptive health industry that meets up with quickly changing times. Investors can also tap into this evolution in healthcare th...
Genomics ETFs have surged of late; here's why
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.
ETF Edge: Big boost for energy ETF
CNBC's Bob Pisani breaks down the biggest exchange-traded funds moves.
While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making stride...
An oil collapse sent Wall Street into a tailspin on Mar 9, indicating that the 11-year-long bull market might soon end. These ETFs may, however, survive the crash.
These sector ETFs gained or lost the least in the coronavirus-induced rout in February.
